Under the Medicare Drug Price Negotiation Program, the HHS secretary negotiates directly with manufacturers on the prices Medicare will pay for pharmaceuticals.

In signing an executive order aimed at reducing U.S. drug prices, President Donald Trump said some prices would be cut in half or more "almost immediately." But the order is light on details of how the plan would be implemented.

Worried about skyrocketing prescription drug costs? Medicare's new spending cap is bringing welcome relief to seniors, with 94% of high-cost users expected to save thousands.

It’s unclear what — if any — impact the Republican president’s executive order will have on millions of Americans who have private health insurance.

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the amount of Medicare spending subject to price negotiation by billions of dollars annually.

President Donald Trump incorrectly placed the blame for high prescription drug prices in the U.S. on foreign nations, making the comments Monday when signing an executive order intended to lower

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year.

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did

UnitedHealth Group will stop compensative brokers and sales agents who sell new Medicare Part D prescription drug plans.

CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26.